Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated:  9/29/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated: 9/29/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated:  9/29/2015
Miami Research Associates
mi
from
Miami, FL
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated: 9/29/2015
Miami Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated:  9/29/2015
Johnson County Clin-Trials
mi
from
Lenexa, KA
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated: 9/29/2015
Johnson County Clin-Trials
mi
from
Lenexa, KA
Click here to add this to my saved trials
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated:  9/29/2015
Meridian Clinical Research
mi
from
Omaha, NE
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated: 9/29/2015
Meridian Clinical Research
mi
from
Omaha, NE
Click here to add this to my saved trials
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated:  9/29/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults
Status: Enrolling
Updated: 9/29/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza
Status: Enrolling
Updated:  9/30/2015
Miami Research Associates
mi
from
Miami, FL
T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza
Status: Enrolling
Updated: 9/30/2015
Miami Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated:  10/5/2015
Accelovance
mi
from
Huntsville, AL
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated: 10/5/2015
Accelovance
mi
from
Huntsville, AL
Click here to add this to my saved trials
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated:  10/5/2015
Accelovance
mi
from
Melbourne, FL
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated: 10/5/2015
Accelovance
mi
from
Melbourne, FL
Click here to add this to my saved trials
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated:  10/5/2015
Accelovance
mi
from
Peoria, IL
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated: 10/5/2015
Accelovance
mi
from
Peoria, IL
Click here to add this to my saved trials
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated:  10/5/2015
Accelovance
mi
from
South Bend, IN
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated: 10/5/2015
Accelovance
mi
from
South Bend, IN
Click here to add this to my saved trials
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated:  10/5/2015
Accelovance
mi
from
Rockville, MD
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
Status: Enrolling
Updated: 10/5/2015
Accelovance
mi
from
Rockville, MD
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Coastal Clinical Research Inc
mi
from
Mobile, AL
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Coastal Clinical Research Inc
mi
from
Mobile, AL
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Benchmark Research, San Francisco
mi
from
Sacramento, CA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Benchmark Research, San Francisco
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
California Research Foundation
mi
from
San Diego, CA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Benchmark Research San Francisco
mi
from
San Francisco, CA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Benchmark Research San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Clinical Research of South Florida
mi
from
Coral Cables, FL
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Clinical Research of South Florida
mi
from
Coral Cables, FL
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
University Clinical Research, Inc.
mi
from
Pembrook Pines, FL
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
University Clinical Research, Inc.
mi
from
Pembrook Pines, FL
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Clinical Research Atlanta
mi
from
Stockbridge, GA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Clinical Research Atlanta
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Johnson County Clin-Trials
mi
from
Lenexa, KA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Johnson County Clin-Trials
mi
from
Lenexa, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Heartland Research Associates, LLC
mi
from
Wichita, KA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Radiant Research
mi
from
St. Louis, MO
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Radiant Research
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Sundance Clinical Research, LLC
mi
from
St. Louis, MO
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Sundance Clinical Research, LLC
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Meridian Clinical Research
mi
from
Omaha, NE
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Meridian Clinical Research
mi
from
Omaha, NE
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Omega Medical Research
mi
from
Warwick, RI
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Palmetto Medical Research
mi
from
Mt. Pleasant, SC
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Palmetto Medical Research
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Clinical Research Associates, Inc. - Nashville
mi
from
Nashville, TN
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Clinical Research Associates, Inc. - Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Benchmark Research, Austin
mi
from
Austin, TX
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Benchmark Research, Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Benchmark Research Ft. Worth
mi
from
Fort Worth, TX
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Benchmark Research Ft. Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Research Across America
mi
from
Plano, TX
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Research Across America
mi
from
Plano, TX
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Benchmark Research, San Angelo
mi
from
San Angelo, TX
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Benchmark Research, San Angelo
mi
from
San Angelo, TX
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Pi-Coor Clinical Research
mi
from
Fairfax, VA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Pi-Coor Clinical Research
mi
from
Fairfax, VA
Click here to add this to my saved trials
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  10/7/2015
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 10/7/2015
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated:  10/7/2015
Heartland Research Associates, LLC
mi
from
Wichita, KA
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated: 10/7/2015
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated:  10/7/2015
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated: 10/7/2015
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated:  10/7/2015
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated: 10/7/2015
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated:  10/7/2015
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated: 10/7/2015
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated:  10/7/2015
Omega Medical Research
mi
from
Warwick, RI
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated: 10/7/2015
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated:  10/7/2015
Research Across America
mi
from
Dallas, TX
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Status: Enrolling
Updated: 10/7/2015
Research Across America
mi
from
Dallas, TX
Click here to add this to my saved trials
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated:  10/7/2015
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated: 10/7/2015
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated:  10/7/2015
Benchmark Research
mi
from
Sacramento, CA
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated: 10/7/2015
Benchmark Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated:  10/7/2015
California Research Foundation
mi
from
San Diego, CA
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated: 10/7/2015
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated:  10/7/2015
Benchmark Research San Francisco
mi
from
San Francisco, CA
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection
Status: Enrolling
Updated: 10/7/2015
Benchmark Research San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials